ArticleHeliyon2024

Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial.

Frans B Mensink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.